Stock Split History
ETFs Holding ABUS »    ABUS Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Arbutus Biopharma is a biopharmaceutical company focused on developing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (HBV). Co. is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. Co.'s pipeline includes: AB-729, a subcutaneously-delivered RNA interference therapeutic product candidate; AB-836, a capsid inhibitor product candidate; and other compounds early in the development process, including back-up capsid inhibitors, oral HBV RNA destabilizers and compounds that inhibit PD-L1. According to our Arbutus Biopharma stock split history records, Arbutus Biopharma has had 1 split.
Arbutus Biopharma stock split history picture
Arbutus Biopharma (ABUS) has 1 split in our Arbutus Biopharma stock split history database. The split for ABUS took place on November 04, 2010. This was a 1 for 5 reverse split, meaning for each 5 shares of ABUS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.

When a company such as Arbutus Biopharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the Arbutus Biopharma stock split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arbutus Biopharma shares, starting with a $10,000 purchase of ABUS, presented on a split-history-adjusted basis factoring in the complete Arbutus Biopharma stock split history. Arbutus Biopharma split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/17/2011
End date: 05/17/2021
Start price/share: $2.77
End price/share: $2.72
Dividends collected/share: $0.00
Total return: -1.81%
Average Annual Total Return: -0.18%
Starting investment: $10,000.00
Ending investment: $9,821.31
Years: 10.01
Date Ratio
11/04/20101 for 5
LM Funding America, Inc. (LMFA)
Foxby Corp. (XFXBX)
InspireMD, Inc. (NSPR)
Aviat Networks, Inc. (AVNW)
Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »
Funds Holding Arbutus Biopharma
Arbutus Biopharma Insider Buying

Arbutus Biopharma Stock Split History | | Copyright © 2013 - 2021, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.